Leukaemia Stem Cells: To seek and destroy
Event details
Molecular and cytotoxic therapies in cancer can often induce remission without achieving a complete disease eradication, potentially resulting in relapse. A better understanding of cell to cell heterogeneity in cancer is crucial for the development of effective therapeutic strategies. By developing a method that allows for simultaneous single-cell RNA sequencing and high-sensitivity targeted mutation detection we have shown that Myeloid Leukaemia stem cells display a high degree of heterogeneity, with cells carrying a distinct transcriptomic signature of “therapy-resistance” being progressively enriched with treatment. I will discuss the approaches that we are undertaking toward the early detection of therapy-resistance events in myeloid leukaemia and the development and refinement of therapeutic strategies targeting leukaemia stem cells.
For more information, contact david.kent@york.ac.uk or dimitris.lagos@york.ac.uk